Niteesh K Choudhry

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1301992/publications.pdf

Version: 2024-02-01

85 papers 4,790 citations

30 h-index 98798 67 g-index

89 all docs 89 docs citations

89 times ranked

6500 citing authors

#	Article	IF	CITATIONS
1	A novel modality for real-time measurement of provider happiness. JAMIA Open, 2022, 5, ooac009.	2.0	O
2	Overcoming Decisional Gaps in High-Risk Prescribing by Junior Physicians Using Simulation-Based Training: Protocol for a Randomized Controlled Trial. JMIR Research Protocols, 2022, 11, e31464.	1.0	2
3	Prescribing decision making by medical residents on night shifts: A qualitative study. Medical Education, 2022, 56, 1032-1041.	2.1	3
4	Leveraging Social Networks for the Assessment and Management of Neurological Patients. Seminars in Neurology, 2022, 42, 136-148.	1.4	9
5	Rationale and design of the Novel Uses of adaptive Designs to Guide provider Engagement in Electronic Health Records (NUDGE-EHR) pragmatic adaptive randomized trial: a trial protocol. Implementation Science, $2021, 16, 9$.	6.9	14
6	Virtual Team Rounding. Academic Medicine, 2021, Publish Ahead of Print, .	1.6	5
7	Preferences for mHealth Technology and Text Messaging Communication in Patients With Type 2 Diabetes: Qualitative Interview Study. Journal of Medical Internet Research, 2021, 23, e25958.	4.3	8
8	Comparison of measures of medication adherence from pharmacy dispensing and insurer claims data. Health Services Research, 2021, , .	2.0	5
9	Evidence-Based Prescribing and Polypharmacy for Patients With Heart Failure. Annals of Internal Medicine, 2021, 174, 1165-1166.	3.9	7
10	Prevalence, predictors, and outcomes of both true- and pseudo-resistant hypertension in the action to control cardiovascular risk in diabetes trial: a cohort study. Hypertension Research, 2021, 44, 1471-1482.	2.7	7
11	Design of the Spine Pain Intervention to Enhance Care Quality And Reduce Expenditure Trial (SPINE) Tj ETQq1 1 C Contemporary Clinical Trials, 2021, 111, 106602.	0.784314 1.8	rgBT Overloc 1
12	Randomised controlled trial targeting habit formation to improve medication adherence to daily oral medications in patients with gout. BMJ Open, 2021, 11, e055930.	1.9	1
13	REinforcement learning to improve non-adherence for diabetes treatments by Optimising Response and Customising Engagement (REINFORCE): study protocol of a pragmatic randomised trial. BMJ Open, 2021, 11, e052091.	1.9	6
14	Using Implementation Science to Optimize the Uptake of Evidence-Based Medicine into Dermatology Practice. Journal of Investigative Dermatology, 2020, 140, 952-958.	0.7	12
15	Prevalence and Impact of Having Multiple Barriers to Medication Adherence in Nonadherent Patients With Poorly Controlled Cardiometabolic Disease. American Journal of Cardiology, 2020, 125, 376-382.	1.6	16
16	The accuracy of self-reported blood pressure in the Medication adherence Improvement Support App For Engagement–Blood Pressure (MedISAFE-BP) trial: Implications for pragmatic trials. American Heart Journal, 2020, 220, 68-72.	2.7	3
17	A systematic overview of systematic reviews evaluating medication adherence interventions. American Journal of Health-System Pharmacy, 2020, 77, 138-147.	1.0	63
18	Recommendations for the Conduct and Reporting of Research Involving Flexible Electronic Health Record–Based Interventions. Annals of Internal Medicine, 2020, 172, S110-S115.	3.9	6

#	Article	IF	Citations
19	Defining a Research Agenda for Layperson Prehospital Hemorrhage Control. JAMA Network Open, 2020, 3, e209393.	5.9	19
20	Not there yet: using data-driven methods to predict who becomes costly among low-cost patients with type 2 diabetes. BMC Endocrine Disorders, 2020, 20, 125.	2.2	5
21	Use of Data-Driven Methods to Predict Long-term Patterns of Health Care Spending for Medicare Patients. JAMA Network Open, 2020, 3, e2020291.	5.9	12
22	Agreement and Accuracy of Medication Persistence Identified by Patient Self-report vs Pharmacy Fill. JAMA Cardiology, 2020, 5, 532.	6.1	8
23	Comparison of a new 3-item self-reported measure of adherence to medication with pharmacy claims data in patients with cardiometabolic disease. American Heart Journal, 2020, 228, 36-43.	2.7	11
24	Association of Potentially Modifiable Diabetes Care Factors With Glycemic Control in Patients With Insulin-Treated Type 2 Diabetes. JAMA Network Open, 2020, 3, e1919645.	5.9	8
25	Effect of Automated Immunization Registry-Based Telephonic Interventions on Adult Vaccination Rates in Community Pharmacies: A Randomized Controlled Trial. Journal of Managed Care & Specialty Pharmacy, 2019, 25, 989-994.	0.9	3
26	Effectiveness of Targeted Insulin-Adherence Interventions for Glycemic Control Using Predictive Analytics Among Patients With Type 2 Diabetes. JAMA Network Open, 2019, 2, e190657.	5.9	19
27	Impact of a novel pharmacist-delivered behavioral intervention for patients with poorly-controlled diabetes: The ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic randomized trial. PLoS ONE, 2019, 14, e0214754.	2.5	28
28	Effect of Medication Co-payment Vouchers on P2Y ₁₂ Inhibitor Use and Major Adverse Cardiovascular Events Among Patients With Myocardial Infarction. JAMA - Journal of the American Medical Association, 2019, 321, 44.	7.4	67
29	General Population vs. Patient Preferences in Anticoagulant Therapy: A Discrete Choice Experiment. Patient, 2019, 12, 235-246.	2.7	6
30	Preventing Postoperative Atrial Fibrillation After Noncardiac Surgery: A Meta-analysis. American Journal of Medicine, 2018, 131, 795-804.e5.	1.5	31
31	Association of a Smartphone Application With Medication Adherence and Blood Pressure Control. JAMA Internal Medicine, 2018, 178, 802.	5.1	214
32	Patterns of opioid initiation at first visits for pain in United States primary care settings. Pharmacoepidemiology and Drug Safety, 2018, 27, 495-503.	1.9	30
33	Patterns and predictors of physician adoption of new cardiovascular drugs. Healthcare, 2018, 6, 33-40.	1.3	16
34	Impact of High Deductible Health Plans on Cardiovascular Medication Adherence and Health Disparities. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004632.	2.2	30
35	Letters designed with behavioural science increase influenza vaccination in Medicare beneficiaries. Nature Human Behaviour, 2018, 2, 743-749.	12.0	56
36	The Promise and Pitfalls of Pragmatic Clinical Trials for Improving Health Care Quality. JAMA Network Open, 2018, 1, e183376.	5.9	16

3

#	Article	IF	CITATIONS
37	Medication Synchronization Programs Improve Adherence To Cardiovascular Medications And Health Care Use. Health Affairs, 2018, 37, 125-133.	5.2	41
38	A Call for a Systems-Thinking Approach to Medication Adherence. JAMA Internal Medicine, 2018, 178, 950.	5.1	17
39	Effect of a Remotely Delivered Tailored Multicomponent Approach to Enhance Medication Taking for Patients With Hyperlipidemia, Hypertension, and Diabetes. JAMA Internal Medicine, 2018, 178, 1182.	5.1	71
40	Rationale and design of the Medication adherence Improvement Support App For Engagement—Blood Pressure (MedISAFE-BP) trial. American Heart Journal, 2017, 186, 40-47.	2.7	38
41	Effect of Reminder Devices on Medication Adherence. JAMA Internal Medicine, 2017, 177, 624.	5.1	160
42	Rationale and design of the ENhancing outcomes through Goal Assessment and Generating Engagement in Diabetes Mellitus (ENGAGE-DM) pragmatic trial. Contemporary Clinical Trials, 2017, 59, 57-63.	1.8	6
43	Patient-Centered Medical Homes and Adherence to Chronic Disease Medications. Annals of Internal Medicine, 2017, 166, 761.	3.9	0
44	Randomized, Controlled Trials in Health Insurance Systems. New England Journal of Medicine, 2017, 377, 957-964.	27.0	35
45	Targeted Adherence Intervention to Reach Glycemic Control with Insulin Therapy for patients with Diabetes (TARGIT-Diabetes): rationale and design of a pragmatic randomised clinical trial. BMJ Open, 2017, 7, e016551.	1.9	10
46	Association Between Patient-Centered Medical Homes and Adherence to Chronic Disease Medications. Annals of Internal Medicine, 2017, 166, 81.	3.9	45
47	Impact of Massachusetts Health Reform on Enrollment Length and Health Care Utilization in the Unsubsidized Individual Market. Health Services Research, 2017, 52, 1118-1137.	2.0	2
48	Hypertension Management in Brazil: Usual Practice in Primary Careâ€"A Meta-Analysis. International Journal of Hypertension, 2017, 2017, 1-9.	1.3	22
49	The Impact of Text Messaging on Medication Adherence and Exercise Among Postmyocardial Infarction Patients: Randomized Controlled Pilot Trial. JMIR MHealth and UHealth, 2017, 5, e110.	3.7	28
50	Persistent opioid use following cesarean delivery: patterns and predictors among opioid-na \tilde{A} -ve women. American Journal of Obstetrics and Gynecology, 2016, 215, 353.e1-353.e18.	1.3	220
51	Limiting the Duration of Opioid Prescriptions. JAMA Internal Medicine, 2016, 176, 583.	5.1	34
52	Rationale and design of the Study of a Tele-pharmacy Intervention for Chronic diseases to Improve Treatment adherence (STIC2IT): A cluster-randomized pragmatic trial. American Heart Journal, 2016, 180, 90-97.	2.7	24
53	Observing versus Predicting: Initial Patterns of Filling Predict Longâ€Term Adherence More Accurately Than Highâ€Dimensional Modeling Techniques. Health Services Research, 2016, 51, 220-239.	2.0	57
54	Design and Rationale of the Best Endovascular Versus Best Surgical Therapy for Patients With Critical Limb Ischemia (BESTâ€CLI) Trial. Journal of the American Heart Association, 2016, 5, .	3.7	158

#	Article	IF	Citations
55	Potentially disruptive life events: what are the immediate impacts on chronic disease management? A case-crossover analysis. BMJ Open, 2016, 6, e010958.	1.9	4
56	Text Messaging and Patient Engagement in an Increasingly Mobile World. Circulation, 2016, 133, 555-556.	1.6	14
57	Prevalence, effectiveness, and characteristics of pharmacy-based medication synchronization programs. American Journal of Managed Care, 2016, 22, 179-86.	1.1	28
58	Association between trajectories of statin adherence and subsequent cardiovascular events. Pharmacoepidemiology and Drug Safety, 2015, 24, 1105-1113.	1.9	76
59	Non-steroidal anti-inflammatory drug administration after coronary artery bypass surgery: utilization persists despite the boxed warning. Pharmacoepidemiology and Drug Safety, 2015, 24, 647-653.	1.9	24
60	Rationale and design of the R andomized E valuation to M easure I mprovements in N on-adherence from Low-Cost D evices (REMIND) trial. Contemporary Clinical Trials, 2015, 43, 53-59.	1.8	11
61	Effects of Xanthine Oxidase Inhibitors on Cardiovascular Disease in Patients with Gout: AÂCohort Study. American Journal of Medicine, 2015, 128, 653.e7-653.e16.	1.5	75
62	Long-Term Cost-Effectiveness of Providing Full Coverage for Preventive Medications After Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 252-259.	2.2	24
63	Medication adherence and healthcare disparities: impact of statin co-payment reduction. American Journal of Managed Care, 2015, 21, 696-704.	1.1	22
64	Attitudes to Mesalamine Questionnaire: A Novel Tool to Predict Mesalamine Nonadherence in Patients with IBD. American Journal of Gastroenterology, 2014, 109, 1850-1855.	0.4	21
65	Initial Choice of Oral Glucose-Lowering Medication for Diabetes Mellitus. JAMA Internal Medicine, 2014, 174, 1955.	5.1	64
66	Clinical Evidence Supporting Pharmacogenomic Biomarker Testing Provided in US Food and Drug Administration Drug Labels. JAMA Internal Medicine, 2014, 174, 1938.	5.1	41
67	Patients' Preferences in Anticoagulant Therapy. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 912-919.	2.2	28
68	Treat or Eat: Food Insecurity, Cost-related Medication Underuse, and Unmet Needs. American Journal of Medicine, 2014, 127, 303-310.e3.	1.5	260
69	Untangling the relationship between medication adherence and post–myocardial infarction outcomes. American Heart Journal, 2014, 167, 51-58.e5.	2.7	162
70	Implementing randomized effectiveness trials in large insurance systems. Journal of Clinical Epidemiology, 2013, 66, S5-S11.	5.0	12
71	Barriers to Insulin Progression Among Patients With Type 2 Diabetes. The Diabetes Educator, 2013, 39, 53-65.	2.5	70
72	Targeting cardiovascular medication adherence interventions. Journal of the American Pharmacists Association: JAPhA, 2012, 52, 381-397.	1.5	58

#	Article	IF	Citations
73	Comparative Costâ€Effectiveness of Interventions to Improve Medication Adherence after Myocardial Infarction. Health Services Research, 2012, 47, 2097-2117.	2.0	34
74	Statin Pharmacogenomics: Opportunities to Improve Patient Outcomes and Healthcare Costs with Genetic Testing. Journal of Personalized Medicine, 2012, 2, 158-174.	2. 5	14
75	Cost-related medication underuse: Prevalence among hospitalized managed care patients. Journal of Hospital Medicine, 2012, 7, 104-109.	1.4	14
76	The Implications of Therapeutic Complexity on Adherence to Cardiovascular Medications. Archives of Internal Medicine, 2011, 171, 814-22.	3.8	172
77	At Pitney Bowes, Value-Based Insurance Design Cut Copayments And Increased Drug Adherence. Health Affairs, 2010, 29, 1995-2001.	5.2	102
78	Four-Dollar Generics — Increased Accessibility, Impaired Quality Assurance. New England Journal of Medicine, 2010, 363, 1885-1887.	27.0	83
79	Assessing The Evidence For Value-Based Insurance Design. Health Affairs, 2010, 29, 1988-1994.	5. 2	74
80	Drug Company–Sponsored Patient Assistance Programs: A Viable Safety Net?. Health Affairs, 2009, 28, 827-834.	5.2	62
81	Measuring concurrent adherence to multiple related medications. American Journal of Managed Care, 2009, 15, 457-64.	1.1	224
82	Trends in adherence to secondary prevention medications in elderly postâ€myocardial infarction patients. Pharmacoepidemiology and Drug Safety, 2008, 17, 1189-1196.	1.9	121
83	Comparison of the Impact of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management Trial on Prescribing Patterns: A Time-Series Analysis. Annals of Pharmacotherapy, 2008, 42, 1563-1572.	1.9	16
84	Systematic Review: The Relationship between Clinical Experience and Quality of Health Care. Annals of Internal Medicine, 2005, 142, 260.	3.9	1,164
85	A perspective on U.S. drug reimportation. Minnesota Medicine, 2005, 88, 46-51.	0.1	0